<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03735121</url>
  </required_header>
  <id_info>
    <org_study_id>BP40657</org_study_id>
    <nct_id>NCT03735121</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Subcutaneous in Patients With Stage IV Non-Small Cell Lung Cancer (IMscin001)</brief_title>
  <official_title>A Two-Part Phase Ib/II Study to Investigate the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Subcutaneous in Patients With Stage IV Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the pharmacokinetics, safety, and efficacy of atezolizumab
      subcutaneous (SC) in patients with Non-Small Cell Lung Cancer (NSCLC). A dose-finding part
      (Part 1) will aim to identify the dose of atezolizumab SC that yields drug exposure that is
      comparable to that of atezolizumab IV. A dose-confirmation part (Part 2) will aim to
      demonstrate the non inferiority of observed drug exposure following treatment with
      atezolizumab SC at the identified dose compared with historical drug exposure following
      treatment with atezolizumab IV.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 27, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 22, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Intervention study model can be sequential or in parallel.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Observed Concentration of Atezolizumab in Serum at Cycle 1 in Part 1</measure>
    <time_frame>Predose of Cycle 2. Cycle length is 21 days.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed Concentration of Atezolizumab in Serum at Cycle 1 in Part 2</measure>
    <time_frame>Predose of Cycle 2. Cycle length is 21 days.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve from Time Zero to Infinity (AUC0-inf) of Atezolizumab in Part 1</measure>
    <time_frame>At Cycle 1. Cycle length is 21 days.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration at the End of a Dosing Interval (Ctrough) of Atezolizumab in Part 1</measure>
    <time_frame>At Cycles 1-4, 7, 11 and 15 and at treatment discontinuation visit. Each cycle is 21 days.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Serum Concentration (Cmax) of Atezolizumab in Part 1</measure>
    <time_frame>At Cycles 1-5, 8, 12 and 16. Each cycle is 21 days.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax) of Atezolizumab in Part 1</measure>
    <time_frame>At Cycles 1-5, 8, 12 and 16. Each cycle is 21 days.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events in Part 1 and Part 2</measure>
    <time_frame>Up to 4.6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) in Part 2</measure>
    <time_frame>Up to 4.6 years</time_frame>
    <description>ORR is defined as the proportion of patients with a partial response (PR) or complete response (CR) as determined by the investigator according to RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) in Part 2</measure>
    <time_frame>Up to 4.6 years</time_frame>
    <description>PFS is defined as the time from the date of study entry to the date of documented disease progression, as determined by the investigator according to RECIST v1.1, or death from any cause, whichever is earlier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) in Part 2</measure>
    <time_frame>Up to 4.6 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Atezolizumab+Bevacizumab+Chemotherapy (Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1: Atezolizumab+rHuPH20 (Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atezolizumab+rHuPH20, followed by Atezolizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Atezolizumab+rHuPH20 (Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atezolizumab+rHuPH20, followed by Atezolizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Atezolizumab+rHuPH20(Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atezolizumab+rHuPH20, followed by Atezolizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Atezolizumab will be administered as per the schedule specified in arm or cohort.</description>
    <arm_group_label>Atezolizumab+Bevacizumab+Chemotherapy (Part 2)</arm_group_label>
    <arm_group_label>Cohort 1: Atezolizumab+rHuPH20 (Part 1)</arm_group_label>
    <arm_group_label>Cohort 2: Atezolizumab+rHuPH20 (Part 1)</arm_group_label>
    <arm_group_label>Cohort 3: Atezolizumab+rHuPH20(Part 1)</arm_group_label>
    <other_name>Tecentriq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab will be administered as per the schedule specified in the arm.</description>
    <arm_group_label>Atezolizumab+Bevacizumab+Chemotherapy (Part 2)</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin will be administered as per the schedule specified in the arm.</description>
    <arm_group_label>Atezolizumab+Bevacizumab+Chemotherapy (Part 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel will be administered as per the schedule specified in the arm.</description>
    <arm_group_label>Atezolizumab+Bevacizumab+Chemotherapy (Part 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rHuPH20</intervention_name>
    <description>rHuPH20 will be administered as per the scheduled specified in the cohort for Part 1.</description>
    <arm_group_label>Cohort 1: Atezolizumab+rHuPH20 (Part 1)</arm_group_label>
    <arm_group_label>Cohort 2: Atezolizumab+rHuPH20 (Part 1)</arm_group_label>
    <arm_group_label>Cohort 3: Atezolizumab+rHuPH20(Part 1)</arm_group_label>
    <other_name>ENHANZE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically documented locally advanced or metastatic NSCLC

          -  Prior platinum-containing regimen or disease recurrence ≤ 6 months since prior
             platinum-based adjuvant/neoadjuvant regimen.

          -  Measurable disease as defined by RECIST v1.1

          -  ECOG Performance Status of 0 or 1

          -  Life expectancy ≥12 weeks

          -  Adequate hematologic and end-organ function

        Exclusion Criteria:

          -  Symptomatic, untreated, or actively progressing CNS metastases

          -  Uncontrolled or symptomatic hypercalcemia

          -  Pregnancy or breastfeeding

          -  Active or history of autoimmune disease or immune deficiency

          -  History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
             pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis

          -  Severe infection ≤ 4 weeks

          -  Treatment with therapeutic oral or IV antibiotics ≤ 2 weeks prior to study treatment

          -  Significant cardiovascular disease

          -  Prior allogeneic stem cell or solid organ transplantation

          -  Treatment with a live, attenuated vaccine ≤ 4 weeks

          -  Treatment with systemic immunostimulatory agents ≤ 4 weeks or 5 half-lives of the drug

          -  Treatment with systemic immunosuppressive medication ≤ 2 weeks

        Additional Exclusion Criteria (Part 2 Only)

          -  No prior anticancer treatment for NSCLC, CD137 agonists or immune checkpoint
             inhibitors

          -  Uncontrolled hypertension, history of hypertensive crisis or hypertensive
             encephalopathy

          -  Significant vascular disease ≤ 6 months

          -  History of hemoptysis ≤ 1 month

          -  Evidence of active bleeding, bleeding diathesis or coagulopathy

          -  Current or recent use of aspirin or with dipyramidole, ticlopidine, clopidogrel, and
             cilostazol

          -  Current use of anticoagulants or thrombolytic agents for therapeutic purposes unstable
             for &gt; 2 weeks prior to enrollment

          -  History of abdominal or tracheosphageal fistula or gastrointestinal perforation ≤ 6
             months

          -  Clinical signs of gastrointestinal obstruction or requirement for routine treatment

          -  Evidence of abdominal free air not explained by paracentesis or recent surgical
             procedure

          -  Serious, non-healing wound, active ulcer, or untreated bone fracture

          -  Proteinuria

          -  Clear tumor infiltration into the thoracic great vessels or cavitation of pulmonary
             lesions

          -  Grade ≥ 2 peripheral neuropathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: BP40657 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bradford Hill Centro de Investigaciones Clinicas; Bradford Hill Centro de Investigaciones Clinicas</name>
      <address>
        <city>Recoleta</city>
        <zip>8420383</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aphm; Cpcet</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ico Rene Gauducheau; Oncologie</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asst Papa Giovanni XXIII; Oncologia Medica</name>
      <address>
        <city>Bergamo</city>
        <state>Lombardia</state>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Clinico Humanitas; Oncologia</name>
      <address>
        <city>Rozzano</city>
        <state>Lombardia</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Centre; Medical Oncology</name>
      <address>
        <city>Seoul</city>
        <zip>135-170</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Riga East Clinical University Hospital Latvian Oncology Centre</name>
      <address>
        <city>Riga</city>
        <zip>LV-1079</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Christchurch Clinical Studies Trust Ltd</name>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne; Klinika Onkologii i Radioterapii</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-214</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regionalny Szpital Specjalistyczny im. W. Bieganskiego; Oddzial Onkologii Klinicznej</name>
      <address>
        <city>Grudziądz</city>
        <zip>86-300</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy; Dept of Pulmonology &amp; subdiv. of oncology</name>
      <address>
        <city>Otwock</city>
        <zip>05-400</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Narodowy Instytut Onkologii im. M. Sklodowskiej-Curie; Oddzial Badan Wczesnych Faz</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria de Navarra; Servicio de Oncologia</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron - PPDS</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz; Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Birmingham Heartlands Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>St James Hospital; Dept of Oncology/Hematology</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Chile</country>
    <country>France</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 7, 2018</study_first_submitted>
  <study_first_submitted_qc>November 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2018</study_first_posted>
  <last_update_submitted>July 6, 2020</last_update_submitted>
  <last_update_submitted_qc>July 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

